Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 139 | 2024 | 2734 | 13.190 |
Why?
|
Carcinoma, Squamous Cell | 87 | 2024 | 4034 | 5.830 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 56 | 2024 | 11524 | 3.150 |
Why?
|
Nasopharyngeal Neoplasms | 6 | 2024 | 286 | 3.040 |
Why?
|
Thyroid Neoplasms | 19 | 2023 | 2282 | 2.930 |
Why?
|
Oropharyngeal Neoplasms | 26 | 2023 | 477 | 2.870 |
Why?
|
Neoplasm Recurrence, Local | 53 | 2023 | 9239 | 2.770 |
Why?
|
Papillomavirus Infections | 28 | 2023 | 1587 | 2.470 |
Why?
|
Mouth Neoplasms | 12 | 2024 | 601 | 1.770 |
Why?
|
Papillomaviridae | 15 | 2021 | 1119 | 1.610 |
Why?
|
Carcinoma, Adenoid Cystic | 8 | 2021 | 252 | 1.600 |
Why?
|
Salivary Gland Neoplasms | 8 | 2020 | 298 | 1.470 |
Why?
|
Cisplatin | 21 | 2024 | 1662 | 1.470 |
Why?
|
Antineoplastic Agents | 32 | 2024 | 13695 | 1.420 |
Why?
|
Laryngeal Neoplasms | 8 | 2014 | 512 | 1.400 |
Why?
|
Taxoids | 19 | 2017 | 666 | 1.310 |
Why?
|
Deglutition Disorders | 8 | 2016 | 605 | 1.270 |
Why?
|
Neoadjuvant Therapy | 10 | 2023 | 2728 | 1.240 |
Why?
|
Human papillomavirus 16 | 11 | 2017 | 262 | 1.140 |
Why?
|
Quinazolines | 11 | 2020 | 1356 | 1.140 |
Why?
|
Carcinoma | 8 | 2024 | 2375 | 1.110 |
Why?
|
Carcinoma, Neuroendocrine | 7 | 2022 | 332 | 1.070 |
Why?
|
Carcinoma, Ductal | 2 | 2018 | 101 | 1.060 |
Why?
|
Acupuncture Therapy | 3 | 2016 | 464 | 0.990 |
Why?
|
Radiotherapy, Intensity-Modulated | 14 | 2022 | 806 | 0.960 |
Why?
|
Neoplasm Metastasis | 22 | 2020 | 4851 | 0.960 |
Why?
|
Carboplatin | 18 | 2019 | 801 | 0.870 |
Why?
|
Protein Kinase Inhibitors | 10 | 2023 | 5535 | 0.850 |
Why?
|
Paclitaxel | 16 | 2019 | 1708 | 0.830 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2019 | 640 | 0.820 |
Why?
|
Combined Modality Therapy | 31 | 2020 | 8642 | 0.800 |
Why?
|
Humans | 271 | 2024 | 744343 | 0.760 |
Why?
|
Disease-Free Survival | 25 | 2021 | 6895 | 0.750 |
Why?
|
Neoplasm Staging | 32 | 2024 | 11031 | 0.740 |
Why?
|
Iodine | 1 | 2022 | 286 | 0.720 |
Why?
|
Fluorouracil | 16 | 2019 | 1619 | 0.720 |
Why?
|
Tumor Burden | 7 | 2022 | 1915 | 0.700 |
Why?
|
Stomatitis | 7 | 2020 | 269 | 0.700 |
Why?
|
Neoplasms, Squamous Cell | 3 | 2009 | 96 | 0.670 |
Why?
|
Patient Selection | 7 | 2018 | 4215 | 0.670 |
Why?
|
Sexual Dysfunction, Physiological | 2 | 2019 | 360 | 0.660 |
Why?
|
Aged | 116 | 2024 | 163280 | 0.660 |
Why?
|
Tretinoin | 1 | 2021 | 517 | 0.640 |
Why?
|
Azacitidine | 1 | 2019 | 347 | 0.620 |
Why?
|
Middle Aged | 122 | 2024 | 213383 | 0.620 |
Why?
|
Piperidines | 4 | 2020 | 1602 | 0.610 |
Why?
|
Deglutition | 3 | 2013 | 197 | 0.580 |
Why?
|
Iodine Radioisotopes | 6 | 2023 | 1032 | 0.580 |
Why?
|
Male | 147 | 2024 | 350118 | 0.580 |
Why?
|
Carcinoma, Medullary | 4 | 2013 | 123 | 0.560 |
Why?
|
Medical Oncology | 6 | 2022 | 2265 | 0.540 |
Why?
|
Aged, 80 and over | 53 | 2021 | 57776 | 0.540 |
Why?
|
Anilides | 3 | 2018 | 408 | 0.520 |
Why?
|
Female | 140 | 2024 | 380194 | 0.510 |
Why?
|
Chemotherapy, Adjuvant | 12 | 2020 | 3479 | 0.500 |
Why?
|
Xerostomia | 6 | 2010 | 95 | 0.500 |
Why?
|
Laryngectomy | 5 | 2018 | 248 | 0.490 |
Why?
|
Immunotherapy | 7 | 2024 | 4445 | 0.490 |
Why?
|
Phenylurea Compounds | 2 | 2017 | 528 | 0.490 |
Why?
|
Treatment Outcome | 50 | 2023 | 63114 | 0.480 |
Why?
|
Proteinuria | 1 | 2017 | 658 | 0.470 |
Why?
|
Radiotherapy, Adjuvant | 13 | 2011 | 1770 | 0.470 |
Why?
|
Alphapapillomavirus | 2 | 2017 | 221 | 0.470 |
Why?
|
Survival Analysis | 20 | 2020 | 10252 | 0.460 |
Why?
|
Clinical Trials, Phase III as Topic | 7 | 2024 | 841 | 0.450 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1097 | 0.450 |
Why?
|
Neck Dissection | 5 | 2011 | 197 | 0.430 |
Why?
|
Adult | 90 | 2022 | 214055 | 0.430 |
Why?
|
Diarrhea | 3 | 2019 | 1348 | 0.420 |
Why?
|
Exanthema | 1 | 2017 | 501 | 0.420 |
Why?
|
Methotrexate | 6 | 2019 | 1727 | 0.410 |
Why?
|
Depsipeptides | 1 | 2012 | 94 | 0.410 |
Why?
|
Quinolines | 1 | 2017 | 732 | 0.410 |
Why?
|
DNA, Viral | 8 | 2019 | 2225 | 0.400 |
Why?
|
Molecular Targeted Therapy | 3 | 2018 | 2727 | 0.390 |
Why?
|
Clinical Trials as Topic | 9 | 2018 | 7913 | 0.380 |
Why?
|
Vascular Neoplasms | 1 | 2012 | 175 | 0.380 |
Why?
|
Adenocarcinoma | 7 | 2022 | 6364 | 0.370 |
Why?
|
Fatigue | 2 | 2017 | 1531 | 0.370 |
Why?
|
Lung Neoplasms | 9 | 2024 | 13102 | 0.370 |
Why?
|
Life Expectancy | 1 | 2017 | 1184 | 0.370 |
Why?
|
Prognosis | 25 | 2024 | 29063 | 0.360 |
Why?
|
Disease Progression | 15 | 2021 | 13284 | 0.360 |
Why?
|
Saliva | 3 | 2019 | 809 | 0.360 |
Why?
|
Spouses | 2 | 2014 | 286 | 0.360 |
Why?
|
Thrombophilia | 1 | 2012 | 305 | 0.350 |
Why?
|
Lymph Nodes | 6 | 2023 | 3474 | 0.350 |
Why?
|
Fecal Incontinence | 2 | 2022 | 239 | 0.350 |
Why?
|
Osteoradionecrosis | 2 | 2021 | 49 | 0.340 |
Why?
|
Carcinoma, Renal Cell | 2 | 2024 | 3143 | 0.340 |
Why?
|
Radiotherapy Dosage | 13 | 2022 | 2879 | 0.340 |
Why?
|
Platinum | 5 | 2023 | 233 | 0.330 |
Why?
|
Amifostine | 2 | 2009 | 41 | 0.330 |
Why?
|
Speech | 1 | 2013 | 540 | 0.320 |
Why?
|
Angiogenesis Inhibitors | 2 | 2016 | 2038 | 0.320 |
Why?
|
Neutropenia | 3 | 2019 | 895 | 0.320 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2018 | 5172 | 0.310 |
Why?
|
Quinuclidines | 1 | 2007 | 24 | 0.310 |
Why?
|
Kidney Neoplasms | 2 | 2024 | 4262 | 0.300 |
Why?
|
Biological Therapy | 1 | 2008 | 138 | 0.300 |
Why?
|
Muscarinic Agonists | 1 | 2007 | 87 | 0.300 |
Why?
|
Neoplasms | 8 | 2023 | 21683 | 0.300 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2012 | 789 | 0.290 |
Why?
|
Kaplan-Meier Estimate | 13 | 2019 | 6538 | 0.290 |
Why?
|
Antibodies, Monoclonal | 13 | 2021 | 9274 | 0.290 |
Why?
|
Urinary Bladder, Overactive | 3 | 2019 | 106 | 0.290 |
Why?
|
Pyridines | 3 | 2018 | 2825 | 0.280 |
Why?
|
Otorhinolaryngologic Neoplasms | 1 | 2006 | 25 | 0.280 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 4 | 2019 | 890 | 0.280 |
Why?
|
Technology, Pharmaceutical | 1 | 2006 | 84 | 0.280 |
Why?
|
Double-Blind Method | 8 | 2024 | 12026 | 0.280 |
Why?
|
Thyroidectomy | 5 | 2018 | 879 | 0.270 |
Why?
|
Esophageal Stenosis | 4 | 2013 | 195 | 0.260 |
Why?
|
Mouth | 2 | 2020 | 374 | 0.260 |
Why?
|
Neuromuscular Agents | 2 | 2019 | 134 | 0.250 |
Why?
|
Retrospective Studies | 39 | 2024 | 77449 | 0.250 |
Why?
|
Antibodies, Viral | 5 | 2019 | 3176 | 0.250 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2021 | 705 | 0.250 |
Why?
|
Neoplasms, Unknown Primary | 2 | 2019 | 104 | 0.240 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2015 | 629 | 0.240 |
Why?
|
Lymphatic Metastasis | 8 | 2015 | 2924 | 0.240 |
Why?
|
Radiation-Protective Agents | 1 | 2003 | 90 | 0.230 |
Why?
|
Botulinum Toxins, Type A | 2 | 2019 | 213 | 0.230 |
Why?
|
Survival Rate | 13 | 2020 | 12788 | 0.230 |
Why?
|
Tropomyosin | 1 | 2023 | 102 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2024 | 9959 | 0.220 |
Why?
|
Retreatment | 4 | 2021 | 610 | 0.220 |
Why?
|
Research Design | 3 | 2015 | 5987 | 0.220 |
Why?
|
Thiophenes | 1 | 2007 | 588 | 0.220 |
Why?
|
Receptor, erbB-2 | 5 | 2020 | 2416 | 0.220 |
Why?
|
CD8-Positive T-Lymphocytes | 5 | 2023 | 4479 | 0.210 |
Why?
|
Nocturia | 1 | 2022 | 19 | 0.210 |
Why?
|
Receptor, trkA | 1 | 2023 | 164 | 0.210 |
Why?
|
Quality of Life | 12 | 2024 | 12804 | 0.210 |
Why?
|
Polymerase Chain Reaction | 6 | 2018 | 6171 | 0.210 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2023 | 1581 | 0.210 |
Why?
|
Standard of Care | 2 | 2023 | 564 | 0.210 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2007 | 284 | 0.200 |
Why?
|
Salvage Therapy | 3 | 2021 | 1275 | 0.200 |
Why?
|
Precancerous Conditions | 3 | 2024 | 975 | 0.200 |
Why?
|
Tongue Neoplasms | 2 | 2013 | 180 | 0.200 |
Why?
|
Herpesvirus 4, Human | 2 | 2024 | 1041 | 0.200 |
Why?
|
Cholinergic Antagonists | 1 | 2022 | 165 | 0.200 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2021 | 2938 | 0.200 |
Why?
|
Larynx | 3 | 2013 | 494 | 0.190 |
Why?
|
Skin Neoplasms | 6 | 2021 | 5686 | 0.190 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 1692 | 0.190 |
Why?
|
Rectal Diseases | 1 | 2022 | 143 | 0.190 |
Why?
|
Oropharynx | 2 | 2013 | 127 | 0.190 |
Why?
|
Perineum | 1 | 2022 | 211 | 0.190 |
Why?
|
Urodynamics | 1 | 2022 | 347 | 0.190 |
Why?
|
Sulfonamides | 4 | 2013 | 1938 | 0.190 |
Why?
|
Cyclin A | 1 | 2000 | 60 | 0.190 |
Why?
|
Dilatation | 2 | 2013 | 291 | 0.190 |
Why?
|
Remission Induction | 5 | 2009 | 2386 | 0.180 |
Why?
|
Rhabdomyoma | 1 | 2020 | 57 | 0.180 |
Why?
|
Gene Fusion | 1 | 2023 | 371 | 0.180 |
Why?
|
Hypopharyngeal Neoplasms | 3 | 2011 | 50 | 0.180 |
Why?
|
Coitus | 1 | 2021 | 133 | 0.180 |
Why?
|
Radiation Injuries | 3 | 2019 | 1180 | 0.180 |
Why?
|
Urethra | 1 | 2022 | 408 | 0.180 |
Why?
|
Interdisciplinary Communication | 1 | 2006 | 950 | 0.180 |
Why?
|
Insulin-Like Growth Factor II | 2 | 2018 | 271 | 0.170 |
Why?
|
Liver Neoplasms, Experimental | 1 | 2000 | 191 | 0.170 |
Why?
|
DNA Mutational Analysis | 2 | 2018 | 4186 | 0.170 |
Why?
|
Delphi Technique | 1 | 2022 | 778 | 0.170 |
Why?
|
Erythropoietin | 1 | 2004 | 726 | 0.170 |
Why?
|
Follow-Up Studies | 18 | 2020 | 39050 | 0.170 |
Why?
|
Mouthwashes | 2 | 2016 | 59 | 0.170 |
Why?
|
Salivary Ducts | 1 | 2018 | 24 | 0.170 |
Why?
|
Iatrogenic Disease | 1 | 2022 | 547 | 0.170 |
Why?
|
Cough | 1 | 2022 | 555 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2019 | 193 | 0.160 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2018 | 2043 | 0.160 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2015 | 323 | 0.160 |
Why?
|
Prospective Studies | 18 | 2022 | 53288 | 0.160 |
Why?
|
Immunohistochemistry | 9 | 2016 | 11366 | 0.160 |
Why?
|
Drug Delivery Systems | 2 | 2008 | 2219 | 0.160 |
Why?
|
Pilot Projects | 8 | 2019 | 8324 | 0.160 |
Why?
|
Sarcopenia | 1 | 2023 | 368 | 0.160 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 1038 | 0.160 |
Why?
|
Algorithms | 3 | 2023 | 13881 | 0.160 |
Why?
|
Melanoma | 4 | 2024 | 5510 | 0.160 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2019 | 323 | 0.160 |
Why?
|
Quinolones | 1 | 2021 | 367 | 0.150 |
Why?
|
Anemia | 2 | 2004 | 1506 | 0.150 |
Why?
|
Muscarinic Antagonists | 1 | 2018 | 137 | 0.150 |
Why?
|
Serologic Tests | 1 | 2019 | 374 | 0.150 |
Why?
|
Antigens, Viral, Tumor | 1 | 1997 | 154 | 0.150 |
Why?
|
Orgasm | 1 | 2017 | 64 | 0.150 |
Why?
|
Papillomavirus E7 Proteins | 3 | 2012 | 123 | 0.150 |
Why?
|
Mutation | 9 | 2022 | 29786 | 0.150 |
Why?
|
Urology | 1 | 2022 | 399 | 0.150 |
Why?
|
Simian virus 40 | 1 | 1997 | 295 | 0.150 |
Why?
|
Clinical Protocols | 2 | 2014 | 1462 | 0.150 |
Why?
|
Diaphragm | 1 | 1999 | 349 | 0.150 |
Why?
|
Young Adult | 18 | 2021 | 56430 | 0.150 |
Why?
|
Platinum Compounds | 1 | 2017 | 96 | 0.140 |
Why?
|
Homocysteine | 3 | 2012 | 647 | 0.140 |
Why?
|
Cryptorchidism | 1 | 1997 | 125 | 0.140 |
Why?
|
Smoking Cessation | 3 | 2015 | 2071 | 0.140 |
Why?
|
SEER Program | 3 | 2019 | 1508 | 0.140 |
Why?
|
Fluorodeoxyglucose F18 | 5 | 2022 | 2016 | 0.140 |
Why?
|
Benzazepines | 1 | 2018 | 326 | 0.140 |
Why?
|
Neoplasm Proteins | 6 | 2018 | 3703 | 0.140 |
Why?
|
Patient Dropouts | 2 | 2012 | 421 | 0.140 |
Why?
|
Hyperbaric Oxygenation | 1 | 2017 | 163 | 0.140 |
Why?
|
Microsatellite Repeats | 1 | 2018 | 802 | 0.140 |
Why?
|
Frameshift Mutation | 1 | 2018 | 399 | 0.140 |
Why?
|
Radiation-Sensitizing Agents | 1 | 1998 | 358 | 0.140 |
Why?
|
Treatment Failure | 3 | 2015 | 2618 | 0.140 |
Why?
|
Genomic Imprinting | 1 | 1997 | 328 | 0.130 |
Why?
|
Administration, Oral | 3 | 2019 | 3913 | 0.130 |
Why?
|
Models, Economic | 1 | 2020 | 713 | 0.130 |
Why?
|
Oncogene Proteins, Viral | 3 | 2012 | 362 | 0.130 |
Why?
|
Oral Hygiene | 1 | 2016 | 126 | 0.130 |
Why?
|
Tumor Microenvironment | 6 | 2024 | 3586 | 0.130 |
Why?
|
Loss of Heterozygosity | 1 | 1997 | 684 | 0.130 |
Why?
|
Photochemotherapy | 2 | 1999 | 807 | 0.130 |
Why?
|
Immunophenotyping | 2 | 2017 | 1880 | 0.130 |
Why?
|
Orchiectomy | 1 | 1997 | 474 | 0.130 |
Why?
|
Maximum Tolerated Dose | 3 | 2019 | 892 | 0.130 |
Why?
|
Palliative Care | 4 | 2013 | 3493 | 0.130 |
Why?
|
Drug Administration Schedule | 4 | 2019 | 4933 | 0.120 |
Why?
|
Genomics | 3 | 2020 | 5720 | 0.120 |
Why?
|
Tooth Diseases | 1 | 2015 | 77 | 0.120 |
Why?
|
Melanoma, Experimental | 1 | 1998 | 561 | 0.120 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2018 | 312 | 0.120 |
Why?
|
Radiation Tolerance | 2 | 2014 | 486 | 0.120 |
Why?
|
Polymorphism, Genetic | 3 | 2012 | 4328 | 0.120 |
Why?
|
Organometallic Compounds | 1 | 1998 | 665 | 0.120 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2018 | 300 | 0.120 |
Why?
|
Lactococcus lactis | 1 | 2013 | 28 | 0.120 |
Why?
|
Testis | 1 | 1997 | 803 | 0.120 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2019 | 3597 | 0.120 |
Why?
|
Morpholines | 1 | 2017 | 571 | 0.120 |
Why?
|
Tumor Suppressor Proteins | 2 | 2014 | 2849 | 0.120 |
Why?
|
Folic Acid | 2 | 2012 | 1300 | 0.110 |
Why?
|
Quality-Adjusted Life Years | 1 | 2020 | 1683 | 0.110 |
Why?
|
Laryngoscopy | 2 | 2012 | 711 | 0.110 |
Why?
|
Aminopyridines | 1 | 2017 | 542 | 0.110 |
Why?
|
Urinary Bladder | 2 | 2022 | 1172 | 0.110 |
Why?
|
Mucous Membrane | 2 | 2019 | 673 | 0.110 |
Why?
|
Marital Status | 1 | 2014 | 437 | 0.110 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2013 | 105 | 0.110 |
Why?
|
Respiratory Function Tests | 1 | 1997 | 1616 | 0.110 |
Why?
|
Chromosome Mapping | 2 | 2000 | 4740 | 0.110 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2014 | 2109 | 0.110 |
Why?
|
Leukoplakia, Oral | 2 | 2024 | 73 | 0.110 |
Why?
|
Radiopharmaceuticals | 5 | 2022 | 2645 | 0.110 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2013 | 188 | 0.100 |
Why?
|
Wounds, Nonpenetrating | 1 | 1999 | 794 | 0.100 |
Why?
|
Down Syndrome | 2 | 2012 | 880 | 0.100 |
Why?
|
Positron-Emission Tomography | 5 | 2022 | 6234 | 0.100 |
Why?
|
Genes, erbB-2 | 1 | 2012 | 162 | 0.100 |
Why?
|
Calcitonin | 2 | 2010 | 336 | 0.100 |
Why?
|
Feasibility Studies | 4 | 2019 | 5078 | 0.100 |
Why?
|
Thyroid Gland | 1 | 2018 | 1173 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3206 | 0.100 |
Why?
|
Etazolate | 1 | 2011 | 1 | 0.100 |
Why?
|
Mutation, Missense | 1 | 2021 | 2564 | 0.100 |
Why?
|
Proto-Oncogenes | 1 | 2012 | 321 | 0.100 |
Why?
|
Esophagoscopy | 1 | 2013 | 390 | 0.100 |
Why?
|
Gastrostomy | 2 | 2011 | 309 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2018 | 8428 | 0.100 |
Why?
|
Radioimmunodetection | 2 | 2001 | 46 | 0.100 |
Why?
|
Cohort Studies | 12 | 2021 | 40561 | 0.100 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2006 | 624 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 9 | 2023 | 20129 | 0.090 |
Why?
|
Carcinoembryonic Antigen | 2 | 2010 | 349 | 0.090 |
Why?
|
Patient Education as Topic | 3 | 2015 | 2278 | 0.090 |
Why?
|
Nervous System Diseases | 1 | 2021 | 1622 | 0.090 |
Why?
|
Axilla | 1 | 2012 | 595 | 0.090 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2011 | 215 | 0.090 |
Why?
|
Mouth Mucosa | 2 | 2013 | 434 | 0.090 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5221 | 0.090 |
Why?
|
Biopsy | 3 | 2018 | 6756 | 0.090 |
Why?
|
Indoles | 1 | 1998 | 1839 | 0.090 |
Why?
|
Incidence | 5 | 2019 | 20947 | 0.090 |
Why?
|
Intubation, Gastrointestinal | 1 | 2010 | 152 | 0.090 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 3 | 2022 | 1624 | 0.090 |
Why?
|
Acetylation | 1 | 2012 | 1085 | 0.090 |
Why?
|
DNA-Binding Proteins | 4 | 2020 | 9648 | 0.090 |
Why?
|
Nutrition Policy | 1 | 2013 | 488 | 0.080 |
Why?
|
Receptors, Somatomedin | 1 | 2008 | 57 | 0.080 |
Why?
|
Health Resources | 1 | 2015 | 911 | 0.080 |
Why?
|
Age Factors | 4 | 2019 | 18370 | 0.080 |
Why?
|
Octreotide | 2 | 2000 | 145 | 0.080 |
Why?
|
Doxorubicin | 1 | 2015 | 2234 | 0.080 |
Why?
|
Meta-Analysis as Topic | 2 | 2016 | 1344 | 0.080 |
Why?
|
Host-Pathogen Interactions | 2 | 2014 | 1477 | 0.080 |
Why?
|
Enteral Nutrition | 2 | 2013 | 763 | 0.080 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7279 | 0.080 |
Why?
|
Codon | 1 | 2010 | 611 | 0.080 |
Why?
|
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2007 | 30 | 0.080 |
Why?
|
Injections, Subcutaneous | 1 | 2009 | 666 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2009 | 10943 | 0.080 |
Why?
|
Pelvis | 2 | 2022 | 730 | 0.080 |
Why?
|
Antineoplastic Protocols | 2 | 2006 | 50 | 0.080 |
Why?
|
Oral Ulcer | 1 | 2008 | 96 | 0.080 |
Why?
|
Sweat | 1 | 2007 | 49 | 0.080 |
Why?
|
Phosphotransferases | 1 | 2008 | 308 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2012 | 1850 | 0.080 |
Why?
|
Tonsillar Neoplasms | 1 | 2007 | 51 | 0.080 |
Why?
|
Survivors | 1 | 2018 | 2291 | 0.080 |
Why?
|
Coronary Artery Bypass | 1 | 1997 | 2289 | 0.080 |
Why?
|
Coronary Disease | 1 | 2022 | 6077 | 0.070 |
Why?
|
Sirolimus | 1 | 2014 | 1564 | 0.070 |
Why?
|
Cancer Care Facilities | 3 | 2019 | 402 | 0.070 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5391 | 0.070 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2018 | 5442 | 0.070 |
Why?
|
Predictive Value of Tests | 8 | 2019 | 15076 | 0.070 |
Why?
|
Pilomatrixoma | 1 | 2006 | 23 | 0.070 |
Why?
|
Relative Biological Effectiveness | 1 | 2008 | 323 | 0.070 |
Why?
|
Neoplasms, Second Primary | 3 | 2010 | 1061 | 0.070 |
Why?
|
Radiation Dosage | 2 | 2022 | 1928 | 0.070 |
Why?
|
Societies, Medical | 1 | 2018 | 3743 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2649 | 0.070 |
Why?
|
Lichen Planus, Oral | 1 | 2007 | 56 | 0.070 |
Why?
|
Dyspepsia | 1 | 2007 | 115 | 0.070 |
Why?
|
Vitamin B 6 | 1 | 2007 | 237 | 0.070 |
Why?
|
Therapeutic Irrigation | 2 | 2019 | 301 | 0.070 |
Why?
|
Ki-67 Antigen | 2 | 2008 | 644 | 0.070 |
Why?
|
Epithelium | 1 | 2011 | 1679 | 0.070 |
Why?
|
Hair Diseases | 1 | 2006 | 74 | 0.070 |
Why?
|
Comorbidity | 3 | 2017 | 10388 | 0.070 |
Why?
|
Enzyme Inhibitors | 1 | 2017 | 3798 | 0.070 |
Why?
|
Tubulin | 1 | 2009 | 695 | 0.070 |
Why?
|
Repressor Proteins | 3 | 2012 | 3023 | 0.070 |
Why?
|
MAP Kinase Signaling System | 1 | 2013 | 1526 | 0.070 |
Why?
|
Lymph Node Excision | 3 | 2001 | 1261 | 0.070 |
Why?
|
Reproducibility of Results | 5 | 2023 | 19905 | 0.070 |
Why?
|
Gastroscopy | 2 | 2004 | 207 | 0.070 |
Why?
|
Liver Neoplasms | 2 | 2000 | 4253 | 0.070 |
Why?
|
Nuclear Proteins | 2 | 2020 | 5853 | 0.070 |
Why?
|
Submandibular Gland | 1 | 2005 | 86 | 0.060 |
Why?
|
Guidelines as Topic | 3 | 2018 | 1405 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2020 | 3158 | 0.060 |
Why?
|
Health Status | 2 | 2017 | 4034 | 0.060 |
Why?
|
United States | 5 | 2020 | 69872 | 0.060 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2007 | 365 | 0.060 |
Why?
|
Hypopharynx | 1 | 2004 | 52 | 0.060 |
Why?
|
Brachytherapy | 1 | 2013 | 1248 | 0.060 |
Why?
|
Radiotherapy, Conformal | 1 | 2008 | 548 | 0.060 |
Why?
|
Vitamin B 12 | 1 | 2007 | 527 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2008 | 578 | 0.060 |
Why?
|
Mucositis | 2 | 2019 | 101 | 0.060 |
Why?
|
Nausea | 1 | 2007 | 673 | 0.060 |
Why?
|
Kidney Transplantation | 3 | 2013 | 4251 | 0.060 |
Why?
|
Radiotherapy | 2 | 2008 | 1533 | 0.060 |
Why?
|
Blood Cells | 1 | 2006 | 309 | 0.060 |
Why?
|
Neoplasm Invasiveness | 1 | 2012 | 3616 | 0.060 |
Why?
|
Genomic Instability | 1 | 2008 | 695 | 0.060 |
Why?
|
Withholding Treatment | 1 | 2008 | 599 | 0.060 |
Why?
|
Pleurodesis | 1 | 2004 | 41 | 0.060 |
Why?
|
Pulmonary Artery | 1 | 2012 | 1912 | 0.060 |
Why?
|
Barium Sulfate | 1 | 2004 | 180 | 0.060 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2004 | 285 | 0.060 |
Why?
|
Patient Preference | 1 | 2011 | 890 | 0.060 |
Why?
|
Time Factors | 9 | 2020 | 40075 | 0.060 |
Why?
|
Mesna | 1 | 2003 | 66 | 0.060 |
Why?
|
Telemedicine | 1 | 2020 | 2872 | 0.060 |
Why?
|
Proportional Hazards Models | 5 | 2019 | 12354 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2012 | 3508 | 0.060 |
Why?
|
Topotecan | 1 | 2003 | 137 | 0.060 |
Why?
|
Postoperative Period | 2 | 2019 | 1842 | 0.060 |
Why?
|
CREB-Binding Protein | 1 | 2023 | 151 | 0.060 |
Why?
|
X-Rays | 1 | 2024 | 301 | 0.060 |
Why?
|
Animals | 14 | 2023 | 168757 | 0.060 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2003 | 115 | 0.050 |
Why?
|
Ifosfamide | 1 | 2003 | 228 | 0.050 |
Why?
|
Pleura | 1 | 2004 | 235 | 0.050 |
Why?
|
Survival | 1 | 2003 | 163 | 0.050 |
Why?
|
Recovery of Function | 2 | 2011 | 2925 | 0.050 |
Why?
|
Carcinoma, Papillary | 1 | 2008 | 783 | 0.050 |
Why?
|
Transcription Factors | 2 | 2020 | 12208 | 0.050 |
Why?
|
Genetic Markers | 2 | 2000 | 2634 | 0.050 |
Why?
|
Valsalva Maneuver | 1 | 2022 | 92 | 0.050 |
Why?
|
Pancreatitis | 2 | 2000 | 1092 | 0.050 |
Why?
|
Adolescent | 11 | 2018 | 85781 | 0.050 |
Why?
|
Receptor, Notch1 | 2 | 2016 | 502 | 0.050 |
Why?
|
Patient Care Planning | 1 | 2008 | 921 | 0.050 |
Why?
|
Psychophysiologic Disorders | 1 | 2004 | 228 | 0.050 |
Why?
|
DNA Methylation | 2 | 2014 | 4286 | 0.050 |
Why?
|
Health Personnel | 1 | 2015 | 3218 | 0.050 |
Why?
|
Interleukin-8 | 1 | 2005 | 690 | 0.050 |
Why?
|
Postoperative Complications | 3 | 2007 | 15295 | 0.050 |
Why?
|
Acetylene | 1 | 2001 | 7 | 0.050 |
Why?
|
Hypertension, Pulmonary | 1 | 2012 | 1537 | 0.050 |
Why?
|
Pandemics | 4 | 2022 | 8388 | 0.050 |
Why?
|
Parotid Gland | 1 | 2022 | 168 | 0.050 |
Why?
|
Genome, Human | 1 | 2014 | 4420 | 0.050 |
Why?
|
Proteome | 1 | 2011 | 1799 | 0.050 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 9438 | 0.050 |
Why?
|
Leucovorin | 1 | 2003 | 628 | 0.050 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2001 | 84 | 0.050 |
Why?
|
Prevalence | 5 | 2019 | 15226 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10262 | 0.050 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2001 | 84 | 0.050 |
Why?
|
Hand Injuries | 1 | 1984 | 242 | 0.050 |
Why?
|
Cyclin A2 | 1 | 2000 | 21 | 0.050 |
Why?
|
Pyrazoles | 2 | 2008 | 1972 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 3923 | 0.050 |
Why?
|
Antibodies, Neoplasm | 2 | 2001 | 286 | 0.050 |
Why?
|
Retinoblastoma Protein | 1 | 2004 | 704 | 0.050 |
Why?
|
Sexual Partners | 2 | 2015 | 730 | 0.050 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 1 | 2000 | 170 | 0.050 |
Why?
|
Esophageal Neoplasms | 2 | 2001 | 1583 | 0.050 |
Why?
|
Manometry | 1 | 2022 | 445 | 0.050 |
Why?
|
Silicon Dioxide | 1 | 2001 | 213 | 0.050 |
Why?
|
Risk Factors | 10 | 2019 | 72290 | 0.050 |
Why?
|
Diagnosis, Differential | 3 | 2012 | 12959 | 0.050 |
Why?
|
Endpoint Determination | 1 | 2003 | 601 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2003 | 648 | 0.040 |
Why?
|
Respiratory Mechanics | 1 | 2004 | 686 | 0.040 |
Why?
|
Organs at Risk | 1 | 2022 | 346 | 0.040 |
Why?
|
Blotting, Southern | 1 | 2000 | 803 | 0.040 |
Why?
|
Technology | 1 | 2022 | 305 | 0.040 |
Why?
|
Anal Canal | 1 | 2022 | 376 | 0.040 |
Why?
|
Cryptogenic Organizing Pneumonia | 1 | 1999 | 29 | 0.040 |
Why?
|
Erythema Nodosum | 1 | 1999 | 30 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 4751 | 0.040 |
Why?
|
Databases, Factual | 1 | 2014 | 7729 | 0.040 |
Why?
|
Base Sequence | 3 | 2016 | 12797 | 0.040 |
Why?
|
Cytokines | 2 | 2016 | 7322 | 0.040 |
Why?
|
Thyroglobulin | 2 | 2010 | 114 | 0.040 |
Why?
|
Smoke Inhalation Injury | 1 | 1999 | 49 | 0.040 |
Why?
|
Genes, Neoplasm | 2 | 2014 | 376 | 0.040 |
Why?
|
Rhenium | 1 | 1998 | 13 | 0.040 |
Why?
|
S Phase | 1 | 2000 | 423 | 0.040 |
Why?
|
Drug Synergism | 1 | 2003 | 1792 | 0.040 |
Why?
|
Pressure | 1 | 2022 | 1203 | 0.040 |
Why?
|
Progesterone | 1 | 2003 | 776 | 0.040 |
Why?
|
Aminolevulinic Acid | 1 | 1999 | 142 | 0.040 |
Why?
|
Smoking | 2 | 2016 | 8987 | 0.040 |
Why?
|
Antipsychotic Agents | 1 | 2012 | 3057 | 0.040 |
Why?
|
Sensitivity and Specificity | 5 | 2019 | 14722 | 0.040 |
Why?
|
Deoxycytidine | 1 | 2003 | 826 | 0.040 |
Why?
|
Urinary Bladder Neck Obstruction | 1 | 2019 | 81 | 0.040 |
Why?
|
Germany | 1 | 2021 | 862 | 0.040 |
Why?
|
Peritonitis | 1 | 2001 | 365 | 0.040 |
Why?
|
Blotting, Northern | 1 | 2000 | 1581 | 0.040 |
Why?
|
Signal Transduction | 3 | 2018 | 23403 | 0.040 |
Why?
|
Technetium | 1 | 1998 | 334 | 0.040 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2023 | 713 | 0.040 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2008 | 2915 | 0.040 |
Why?
|
Hypokalemia | 1 | 2019 | 153 | 0.040 |
Why?
|
Mice | 6 | 2023 | 81183 | 0.040 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2000 | 599 | 0.040 |
Why?
|
Skin Temperature | 1 | 1998 | 93 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2019 | 401 | 0.040 |
Why?
|
beta Catenin | 1 | 2023 | 1059 | 0.040 |
Why?
|
Cell Transformation, Viral | 1 | 2019 | 565 | 0.040 |
Why?
|
Somatostatin | 1 | 2000 | 459 | 0.040 |
Why?
|
Pelvic Neoplasms | 1 | 2000 | 254 | 0.040 |
Why?
|
Constipation | 1 | 2022 | 546 | 0.040 |
Why?
|
Body Fluids | 1 | 2019 | 319 | 0.040 |
Why?
|
Radiography | 3 | 2014 | 7023 | 0.040 |
Why?
|
In Situ Hybridization | 2 | 2013 | 1950 | 0.040 |
Why?
|
Urinary Bladder, Neurogenic | 1 | 2019 | 165 | 0.040 |
Why?
|
Rectum | 1 | 2022 | 904 | 0.040 |
Why?
|
Risk Assessment | 4 | 2019 | 23338 | 0.040 |
Why?
|
Cell Line, Tumor | 2 | 2023 | 16689 | 0.040 |
Why?
|
Random Allocation | 2 | 2001 | 2429 | 0.040 |
Why?
|
Neck | 2 | 2016 | 697 | 0.040 |
Why?
|
Cell Cycle Proteins | 1 | 2008 | 3462 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2020 | 11124 | 0.040 |
Why?
|
Bandages | 1 | 1999 | 266 | 0.040 |
Why?
|
Vagina | 1 | 2022 | 825 | 0.040 |
Why?
|
Mandible | 1 | 2021 | 740 | 0.040 |
Why?
|
Jaw | 1 | 2017 | 96 | 0.040 |
Why?
|
Hyperhomocysteinemia | 2 | 2007 | 124 | 0.040 |
Why?
|
Anorexia | 1 | 2017 | 161 | 0.040 |
Why?
|
Catheterization | 1 | 2022 | 1470 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 17446 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2008 | 876 | 0.040 |
Why?
|
Placebos | 1 | 2021 | 1676 | 0.040 |
Why?
|
Mice, Transgenic | 2 | 2000 | 9734 | 0.030 |
Why?
|
Sensation Disorders | 1 | 2017 | 155 | 0.030 |
Why?
|
Crosses, Genetic | 1 | 1997 | 791 | 0.030 |
Why?
|
Estrogens | 1 | 2003 | 1566 | 0.030 |
Why?
|
Immunoglobulin G | 2 | 2015 | 4560 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2004 | 1179 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 53 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3870 | 0.030 |
Why?
|
CpG Islands | 1 | 2000 | 1172 | 0.030 |
Why?
|
Abdominal Muscles | 1 | 1996 | 166 | 0.030 |
Why?
|
Neutron Capture Therapy | 1 | 2015 | 6 | 0.030 |
Why?
|
Brazil | 2 | 2012 | 1270 | 0.030 |
Why?
|
Intraoperative Care | 1 | 2000 | 767 | 0.030 |
Why?
|
Cell Cycle | 1 | 2004 | 2967 | 0.030 |
Why?
|
Injections | 1 | 2019 | 840 | 0.030 |
Why?
|
Cross-Sectional Studies | 4 | 2022 | 25043 | 0.030 |
Why?
|
International Agencies | 1 | 2016 | 240 | 0.030 |
Why?
|
Infant | 6 | 2016 | 35136 | 0.030 |
Why?
|
Social Participation | 1 | 2017 | 173 | 0.030 |
Why?
|
Tobacco Use Disorder | 2 | 2011 | 688 | 0.030 |
Why?
|
Photosensitizing Agents | 1 | 1999 | 602 | 0.030 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2021 | 570 | 0.030 |
Why?
|
Nanotechnology | 1 | 2001 | 710 | 0.030 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2000 | 709 | 0.030 |
Why?
|
Hormones | 1 | 1999 | 889 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2016 | 2948 | 0.030 |
Why?
|
Child, Preschool | 6 | 2016 | 41006 | 0.030 |
Why?
|
Eating | 2 | 2013 | 1536 | 0.030 |
Why?
|
Administration, Intravesical | 1 | 2014 | 91 | 0.030 |
Why?
|
Radiation Oncology | 1 | 2021 | 555 | 0.030 |
Why?
|
DNA Helicases | 1 | 2020 | 859 | 0.030 |
Why?
|
Receptor, Notch2 | 1 | 2015 | 89 | 0.030 |
Why?
|
ras GTPase-Activating Proteins | 1 | 2015 | 101 | 0.030 |
Why?
|
Single-Blind Method | 1 | 1998 | 1590 | 0.030 |
Why?
|
Genotype | 3 | 2012 | 12951 | 0.030 |
Why?
|
Cyclin D1 | 1 | 2016 | 463 | 0.030 |
Why?
|
Gene Dosage | 1 | 2018 | 1252 | 0.030 |
Why?
|
Polymers | 1 | 2001 | 1621 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2020 | 857 | 0.030 |
Why?
|
Schizophrenia | 1 | 2012 | 6882 | 0.030 |
Why?
|
Analysis of Variance | 3 | 2011 | 6365 | 0.030 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2004 | 6038 | 0.030 |
Why?
|
Rats, Wistar | 3 | 2004 | 1901 | 0.030 |
Why?
|
Gene Frequency | 2 | 2012 | 3588 | 0.030 |
Why?
|
Phosphorylation | 1 | 2004 | 8436 | 0.030 |
Why?
|
Psychometrics | 1 | 2022 | 3002 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2003 | 2716 | 0.030 |
Why?
|
Logistic Models | 2 | 2019 | 13408 | 0.030 |
Why?
|
Methylmalonic Acid | 1 | 2012 | 49 | 0.030 |
Why?
|
Virus Integration | 1 | 2014 | 299 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 20822 | 0.030 |
Why?
|
Niacinamide | 1 | 2014 | 417 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 1998 | 1375 | 0.030 |
Why?
|
Burns | 1 | 1984 | 1815 | 0.030 |
Why?
|
Apoptosis | 1 | 2008 | 9727 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2015 | 4803 | 0.030 |
Why?
|
Immunity | 1 | 2018 | 1012 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2018 | 15165 | 0.030 |
Why?
|
Pancreas Transplantation | 1 | 2013 | 187 | 0.030 |
Why?
|
Interleukin-3 | 1 | 2013 | 444 | 0.030 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2012 | 230 | 0.030 |
Why?
|
Quality Improvement | 2 | 2019 | 3749 | 0.030 |
Why?
|
History, 21st Century | 1 | 2018 | 1534 | 0.030 |
Why?
|
Recurrence | 2 | 2020 | 8340 | 0.030 |
Why?
|
Lebanon | 1 | 2012 | 229 | 0.030 |
Why?
|
Administration, Topical | 1 | 2013 | 690 | 0.030 |
Why?
|
Indazoles | 1 | 2013 | 289 | 0.030 |
Why?
|
Dimerization | 1 | 2013 | 893 | 0.020 |
Why?
|
Consensus | 1 | 2021 | 2959 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2013 | 677 | 0.020 |
Why?
|
Vitamin B 12 Deficiency | 1 | 2012 | 116 | 0.020 |
Why?
|
Antibody Formation | 1 | 2016 | 1402 | 0.020 |
Why?
|
Disease Models, Animal | 3 | 2001 | 18029 | 0.020 |
Why?
|
Carbon | 1 | 2015 | 687 | 0.020 |
Why?
|
Case-Control Studies | 3 | 2016 | 21746 | 0.020 |
Why?
|
Androgen Antagonists | 1 | 2020 | 1377 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2007 | 15519 | 0.020 |
Why?
|
Cotinine | 1 | 2011 | 206 | 0.020 |
Why?
|
Up-Regulation | 1 | 2000 | 4217 | 0.020 |
Why?
|
Cell Movement | 1 | 2023 | 5217 | 0.020 |
Why?
|
Colorectal Neoplasms | 2 | 2001 | 6773 | 0.020 |
Why?
|
Cicatrix | 1 | 1996 | 764 | 0.020 |
Why?
|
Syndrome | 1 | 2017 | 3251 | 0.020 |
Why?
|
Transplantation, Homologous | 2 | 2011 | 4776 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2019 | 1941 | 0.020 |
Why?
|
Severity of Illness Index | 4 | 2011 | 15540 | 0.020 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2010 | 88 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2013 | 2942 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2018 | 1660 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2018 | 2015 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2016 | 1607 | 0.020 |
Why?
|
Alzheimer Disease | 1 | 2011 | 8037 | 0.020 |
Why?
|
Models, Genetic | 1 | 2000 | 3494 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4397 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2022 | 3690 | 0.020 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2010 | 428 | 0.020 |
Why?
|
Esophagitis | 1 | 2010 | 152 | 0.020 |
Why?
|
Viral Load | 1 | 2018 | 3299 | 0.020 |
Why?
|
False Positive Reactions | 2 | 2004 | 981 | 0.020 |
Why?
|
Dyspnea | 1 | 2017 | 1303 | 0.020 |
Why?
|
Child | 6 | 2016 | 77709 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2133 | 0.020 |
Why?
|
Albumins | 1 | 2012 | 569 | 0.020 |
Why?
|
Dermatitis | 1 | 2010 | 197 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 135 | 0.020 |
Why?
|
Documentation | 1 | 2015 | 871 | 0.020 |
Why?
|
Endometriosis | 1 | 1996 | 839 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7301 | 0.020 |
Why?
|
Heart Failure | 1 | 2012 | 10900 | 0.020 |
Why?
|
Carbon Monoxide | 1 | 2011 | 531 | 0.020 |
Why?
|
Preoperative Care | 1 | 1997 | 2250 | 0.020 |
Why?
|
Diet | 1 | 2006 | 7939 | 0.020 |
Why?
|
Boston | 2 | 2011 | 9313 | 0.020 |
Why?
|
Cell Survival | 1 | 1998 | 5882 | 0.020 |
Why?
|
HIV Infections | 1 | 2014 | 16718 | 0.020 |
Why?
|
Fibrosis | 2 | 2005 | 2029 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2013 | 847 | 0.020 |
Why?
|
Chi-Square Distribution | 2 | 2007 | 3508 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 2007 | 378 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 1799 | 0.020 |
Why?
|
Drug Resistance, Bacterial | 1 | 2014 | 1035 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2016 | 25625 | 0.020 |
Why?
|
Mice, Nude | 1 | 2013 | 3689 | 0.020 |
Why?
|
Adenoma, Oxyphilic | 1 | 2008 | 143 | 0.020 |
Why?
|
Protein Conformation | 1 | 2014 | 4011 | 0.020 |
Why?
|
Alleles | 1 | 1997 | 6933 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 1997 | 2569 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 1998 | 2541 | 0.020 |
Why?
|
Ligands | 1 | 2013 | 3282 | 0.020 |
Why?
|
Cyclooxygenase 2 | 1 | 2008 | 611 | 0.020 |
Why?
|
Nutrition Assessment | 1 | 2009 | 723 | 0.020 |
Why?
|
Dinoprostone | 1 | 2008 | 600 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2001 | 4256 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2013 | 1359 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2007 | 684 | 0.020 |
Why?
|
Laparoscopy | 1 | 1997 | 2151 | 0.020 |
Why?
|
Infusions, Intravenous | 2 | 2001 | 2274 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2010 | 1758 | 0.020 |
Why?
|
Histology | 1 | 2004 | 16 | 0.020 |
Why?
|
Functional Residual Capacity | 1 | 2004 | 68 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2022 | 11483 | 0.020 |
Why?
|
Pharynx | 1 | 2007 | 413 | 0.020 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2008 | 324 | 0.020 |
Why?
|
Occlusive Dressings | 1 | 1984 | 50 | 0.010 |
Why?
|
Lung Compliance | 1 | 2004 | 195 | 0.010 |
Why?
|
Length of Stay | 1 | 1997 | 6309 | 0.010 |
Why?
|
Pharyngeal Diseases | 1 | 2004 | 133 | 0.010 |
Why?
|
Postoperative Care | 1 | 2010 | 1486 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2016 | 3966 | 0.010 |
Why?
|
Organ Specificity | 1 | 2008 | 2008 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 2003 | 382 | 0.010 |
Why?
|
Physical Examination | 1 | 2009 | 1237 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2703 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2010 | 35421 | 0.010 |
Why?
|
Counseling | 1 | 2011 | 1523 | 0.010 |
Why?
|
Salivary Glands | 1 | 2004 | 229 | 0.010 |
Why?
|
Linear Models | 1 | 2012 | 5952 | 0.010 |
Why?
|
Pain | 1 | 2017 | 4986 | 0.010 |
Why?
|
Liver | 1 | 1997 | 7474 | 0.010 |
Why?
|
Data Collection | 1 | 2011 | 3341 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 1434 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 18111 | 0.010 |
Why?
|
Creatinine | 1 | 2007 | 1919 | 0.010 |
Why?
|
Pyrimidines | 1 | 2013 | 2942 | 0.010 |
Why?
|
Heterozygote | 1 | 2007 | 2804 | 0.010 |
Why?
|
Constriction, Pathologic | 1 | 2004 | 1107 | 0.010 |
Why?
|
Cell Death | 1 | 2006 | 1706 | 0.010 |
Why?
|
Thorax | 1 | 2004 | 547 | 0.010 |
Why?
|
Intraoperative Period | 1 | 2001 | 520 | 0.010 |
Why?
|
Rats | 3 | 2004 | 24260 | 0.010 |
Why?
|
Surface-Active Agents | 1 | 2001 | 159 | 0.010 |
Why?
|
Respiratory System | 1 | 2004 | 557 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2007 | 2203 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2015 | 4371 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 1998 | 21827 | 0.010 |
Why?
|
Menstrual Cycle | 1 | 2003 | 551 | 0.010 |
Why?
|
Medical History Taking | 1 | 2004 | 783 | 0.010 |
Why?
|
Phenotype | 1 | 1997 | 16365 | 0.010 |
Why?
|
Patient Care Team | 1 | 2011 | 2531 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2004 | 973 | 0.010 |
Why?
|
Burkitt Lymphoma | 1 | 2001 | 327 | 0.010 |
Why?
|
Hematologic Neoplasms | 1 | 2011 | 1832 | 0.010 |
Why?
|
Patient Compliance | 1 | 2009 | 2684 | 0.010 |
Why?
|
Gene Deletion | 1 | 2007 | 2751 | 0.010 |
Why?
|
Acute Disease | 2 | 2000 | 7149 | 0.010 |
Why?
|
False Negative Reactions | 1 | 2000 | 588 | 0.010 |
Why?
|
Health Promotion | 1 | 2011 | 2205 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 2011 | 2957 | 0.010 |
Why?
|
Skin Transplantation | 1 | 1984 | 1074 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2013 | 3336 | 0.010 |
Why?
|
Medical Records | 1 | 2004 | 1413 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2015 | 4468 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 1984 | 1681 | 0.010 |
Why?
|
Clone Cells | 1 | 2001 | 1692 | 0.010 |
Why?
|
Observer Variation | 1 | 2004 | 2593 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3920 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2009 | 1797 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2001 | 2645 | 0.010 |
Why?
|
Anastomosis, Surgical | 1 | 2001 | 987 | 0.010 |
Why?
|
Esophagectomy | 1 | 2001 | 447 | 0.010 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 1953 | 0.010 |
Why?
|
Postpartum Period | 1 | 2003 | 1086 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2001 | 1677 | 0.010 |
Why?
|
Probability | 1 | 2001 | 2505 | 0.010 |
Why?
|
Surgical Flaps | 1 | 1984 | 1640 | 0.010 |
Why?
|
Biosensing Techniques | 1 | 2001 | 668 | 0.010 |
Why?
|
Lymphoma, B-Cell | 1 | 2001 | 931 | 0.010 |
Why?
|
Inflammation | 2 | 2005 | 10638 | 0.010 |
Why?
|
Environmental Monitoring | 1 | 2001 | 1414 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 1998 | 2031 | 0.010 |
Why?
|
Reference Values | 1 | 2001 | 4982 | 0.010 |
Why?
|
Chronic Disease | 1 | 2007 | 9146 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2004 | 3229 | 0.010 |
Why?
|
Sex Factors | 1 | 1984 | 10397 | 0.010 |
Why?
|
Pregnancy | 2 | 2003 | 29144 | 0.010 |
Why?
|
Cesarean Section | 1 | 1996 | 1365 | 0.000 |
Why?
|
Lung | 1 | 1999 | 9856 | 0.000 |
Why?
|